Cargando…

Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study

PURPOSE: Tobramycin is an aminoglycoside antibiotic of which the 24 h exposure correlates with efficacy. Recently, we found that clearance of the aminoglycoside gentamicin correlates with total body weight (TBW). In this study, we investigate the full pharmacokinetic profile of tobramycin in obese a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smit, Cornelis, Wasmann, Roeland E., Wiezer, Marinus J., van Dongen, Hendricus P. A., Mouton, Johan W., Brüggemann, Roger J. M., Knibbe, Catherijne A. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542779/ https://www.ncbi.nlm.nih.gov/pubmed/31147853 http://dx.doi.org/10.1007/s11095-019-2651-2

Ejemplares similares

Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals
por: Smit, Cornelis, et al.
Publicado: (2020)

A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients
por: Smit, Cornelis, et al.
Publicado: (2019)

Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study
por: van Rhee, Koen P., et al.
Publicado: (2022)

Implications for IV posaconazole dosing in the era of obesity
por: Wasmann, Roeland E, et al.
Publicado: (2020)

Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals
por: Wasmann, Roeland E, et al.
Publicado: (2020)

Vancomycin Clearance in Obese Adults is not Predictive of Clearance in Obese Adolescents
por: Zhang, Tan, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017)

Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1–18 Years
por: Smit, Cornelis, et al.
Publicado: (2021)

Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function
por: Smit, Cornelis, et al.
Publicado: (2020)

Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults
por: van Rongen, Anne, et al.
Publicado: (2017)

Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers
por: Brill, Margreke J. E., et al.
Publicado: (2014)

Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial
por: van Rongen, Anne, et al.
Publicado: (2018)

Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide
por: de Hoogd, Sjoerd, et al.
Publicado: (2017)

The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery
por: Brill, Margreke J., et al.
Publicado: (2015)

Does Weight Impact Anidulafungin Pharmacokinetics?
por: Lempers, Vincent J., et al.
Publicado: (2016)

Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties
por: Smit, Cornelis, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies
por: Wasmann, Roeland E., et al.
Publicado: (2020)

Predictors of Insulin Resistance in Children versus Adolescents with Obesity
por: Lentferink, Yvette E., et al.
Publicado: (2017)

LBODP083 Pharmacokinetics Of Metformin In Obese Non-diabetic Youth: Drug Clearance Increases With Severity Of Obesity
por: Halpin, Kelsee, et al.
Publicado: (2022)

Increased Arterial Stiffness in Adolescents With Obesity
por: Lentferink, Yvette E., et al.
Publicado: (2019)

An Integrated Population Pharmacokinetic Meta-Analysis of Propofol in Morbidly Obese and Nonobese Adults, Adolescents, and Children
por: Diepstraten, J, et al.
Publicado: (2013)

The Predictive Value of Glomerular Filtration Rate-Based Scaling of Pediatric Clearance and Doses for Drugs Eliminated by Glomerular Filtration with Varying Protein-Binding Properties
por: Cristea, Sinziana, et al.
Publicado: (2020)

METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents – study protocol of a randomized controlled study
por: van der Aa, Marloes P, et al.
Publicado: (2014)

Asthma medication in children who are overweight/obese: justified treatment?
por: Lentferink, Yvette E., et al.
Publicado: (2019)

Pharmacokinetic analysis of topical tobramycin in equine tears by automated immunoassay
por: Czerwinski, Sarah L, et al.
Publicado: (2012)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Oral drug dosing following bariatric surgery: General concepts and specific dosing advice
por: Kingma, Jurjen S., et al.
Publicado: (2021)

Comment on: "Preterm Physiologically Based Pharmacokinetic Model, Part I and Part II”
por: Völler, Swantje, et al.
Publicado: (2021)

Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children
por: Hartman, Stan J. F., et al.
Publicado: (2022)

Comparison of different pain scoring systems in critically ill patients in a general ICU
por: Ahlers, Sabine JGM, et al.
Publicado: (2008)

Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis Session (ESRD Study)
por: Giroux, Marjolaine, et al.
Publicado: (2021)

Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen
por: van Rongen, Anne, et al.
Publicado: (2016)

Population pharmacokinetic model for once‐daily intravenous busulfan in pediatric subjects describing time‐associated clearance
por: Lawson, Rachael, et al.
Publicado: (2022)

Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients
por: Brill, MJE, et al.
Publicado: (2015)

Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?
por: Calvier, Elisa A. M., et al.
Publicado: (2016)

Evaluation of propofol anesthesia in morbidly obese children and adolescents
por: Chidambaran, Vidya, et al.
Publicado: (2013)

Pharmacokinetics of intravenous and inhaled salbutamol and tobramycin: An exploratory study to investigate the potential of exhaled breath condensate as a matrix for pharmacokinetic analysis
por: Kruizinga, Matthijs D., et al.
Publicado: (2020)

A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children
por: Brussee, Janneke M., et al.
Publicado: (2019)

Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models
por: Berton, Mattia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4o4ofngqu1d2jrqfqdlk9gqu0q